



89000602

JUL 31 2001

T2001-39
89000602

NOVARTIS

APPROVED

Anafranil®
clomipramine hydrochloride

Capsules


Rx only

Prescribing Information

DESCRIPTION

Anafranil, clomipramine hydrochloride, is an antidepressant drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. Anafranil is available as capsules of 25, 50, and 75 mg for oral administration.

Clomipramine hydrochloride is 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride, and its structural formula is



Clomipramine hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, in methanol, and in methylene chloride, and insoluble in ethyl ether and in hexane. Its molecular weight is 351.3.

Inactive Ingredients. D&C Red No. 33 (25-mg capsules only), D&C Yellow No. 10, FD&C Blue No. 1 (50-mg capsules only), FD&C Yellow No. 6, gelatin, magnesium stearate, methylparaben, propylparaben, silicon dioxide, sodium lauryl sulfate, starch (corn), and titanium dioxide.

CLINICAL PHARMACOLOGY

Pharmacodynamics

Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought to be important.

Pharmacokinetics

Absorption/Bioavailability: CMI from Anafranil capsules is as bioavailable as CMI from a solution. The bioavailability of CMI from capsules is not significantly affected by food.

In a dose proportionality study involving multiple CMI doses, steady-state plasma concentrations (C_{ss}) and area-under-plasma-concentration-time curves (AUC) of CMI and CMI's major active metabolite, desmethylclomipramine (DMI), were not proportional to dose over the ranges evaluated, i.e., between 25-100 mg/day and between 25-150 mg/day, although C_{ss} and AUC are approximately linearly related to dose between 100-150 mg/day. The relationship between dose and CMI/DMI concentrations at higher daily doses has not been systematically assessed, but if there is significant dose dependency at doses above 150 mg/day, there is the potential for dramatically higher C_{ss} and AUC even for patients dosed within the recommended range. This may pose a potential risk to some patients (see WARNINGS and PRECAUTIONS, Drug Interactions).

After a single 50-mg oral dose, maximum plasma concentrations of CMI occur within 2-8 hours (mean, 4.7 hr) and range from 56 ng/mL to 154 ng/mL (mean, 92 ng/mL). After multiple daily doses of 150 mg of Anafranil, steady-state maximum plasma concentrations range from 94 ng/mL to 339 ng/mL (mean, 218 ng/mL) for CMI and from 134 ng/mL to 532 ng/mL (mean, 274 ng/mL) for DMI. No pharmacokinetic information is available for doses ranging from 150 mg/day to 250 mg/day, the maximum recommended daily dose.

Distribution: CMI distributes into cerebrospinal fluid (CSF) and brain and into breast milk. DMI also distributes into CSF, with a mean CSF/plasma ratio of 2.6. The protein binding of CMI is approximately 97%, principally to albumin, and is independent of CMI concentration. The interaction between CMI and other highly protein-bound drugs has not been fully evaluated, but may be important (see PRECAUTIONS, Drug Interactions).

Metabolism: CMI is extensively biotransformed to DMI and other metabolites and their glucuronide conjugates. DMI is pharmacologically active, but its effects on OCD behaviors are unknown. These metabolites are excreted in urine and feces, following biliary elimination. After a 25-mg radiolabeled dose of CMI in two subjects, 60% and 51%, respectively, of the dose were recovered in the urine and 32% and 24%, respectively, in feces. In the same study, the combined urinary recoveries of CMI and DMI were only about 0.8%-1.3% of the dose administered. CMI does not induce drug-metabolizing enzymes, as measured by antipyrine half-life.

Elimination: Evidence that the C_{ss} and AUC for CMI and DMI may increase disproportionately with increasing oral doses suggests that the metabolism of CMI and DMI may be capacity limited. This fact must be considered in assessing the estimates of the pharmacokinetic parameters presented below, as these were obtained in individuals exposed to doses of 150 mg. If the pharmacokinetics of CMI and DMI are nonlinear at doses above 150 mg, their elimination half-lives may be considerably lengthened at doses near the upper end of the recommended dosing range (i.e., 200 mg/day to 250 mg/day). Consequently, CMI and DMI may accumulate, and this accumulation may increase the incidence of any dose- or plasma-concentration-dependent adverse reactions, in particular seizures (see WARNINGS).

After a 150-mg dose, the half-life of CMI ranges from 19 hours to 37 hours (mean, 32 hr) and that of DMI ranges from 54 hours to 77 hours (mean, 69 hr). Steady-state levels after multiple dosing are typically reached within 7-14 days for CMI. Plasma concentrations of the metabolite exceed the parent drug on multiple dosing. After multiple dosing with 150 mg/day, the accumulation factor for CMI is approximately 2.5 and for DMI is 4.6. Importantly, it may take two weeks or longer to achieve this extent of accumulation at constant dosing because of the relatively long elimination half-lives of CMI and DMI (see DOSAGE AND ADMINISTRATION). The effects of hepatic and renal impairment on the disposition of Anafranil have not been determined.

Interactions: Coadministration of haloperidol with CMI increases plasma concentrations of

CMI. Coadministration of CMI with phenobarbital increases plasma concentrations of phenobarbital (see PRECAUTIONS, Drug Interactions). Younger subjects (18-40 years of age) tolerated CMI better and had significantly lower steady-state plasma concentrations, compared with subjects over 65 years of age. Children under 15 years of age had significantly lower plasma concentration/dose ratios, compared with adults. Plasma concentrations of CMI were significantly lower in smokers than in nonsmokers.

INDICATIONS AND USAGE

Anafranil is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD.

Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable.

The effectiveness of Anafranil for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10-17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents.

The effectiveness of Anafranil for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use Anafranil for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

CONTRAINDICATIONS

Anafranil is contraindicated in patients with a history of hypersensitivity to Anafranil or other tricyclic antidepressants.

Anafranil should not be given in combination, or within 14 days before or after treatment, with a monoamine oxidase (MAO) inhibitor. Hyperpyretic crisis, seizures, coma, and death have been reported in patients receiving such combinations.

Anafranil is contraindicated during the acute recovery period after a myocardial infarction.

WARNINGS

Seizures

During premarket evaluation, seizure was identified as the most significant risk of Anafranil use.

The observed cumulative incidence of seizures among patients exposed to Anafranil at doses up to 300 mg/day was 0.64% at 90 days, 1.12% at 180 days, and 1.45% at 365 days. The cumulative rates correct the crude rate of 0.7% (25 of 3519 patients) for the variable duration of exposure in clinical trials.

Although dose appears to be a predictor of seizure, there is a confounding of dose and duration of exposure, making it difficult to assess independently the effect of either factor alone. The ability to predict the occurrence of seizures in subjects exposed to doses of CMI greater than 250 mg is limited, given that the plasma concentration of CMI may be dose-dependent and may vary among subjects given the same dose. Nevertheless, prescribers are advised to limit the daily dose to a maximum of 250 mg in adults and 3 mg/kg (or 200 mg) in children and adolescents (see DOSAGE AND ADMINISTRATION).

Caution should be used in administering Anafranil to patients with a history of seizures or other predisposing factors, e.g., brain damage of varying etiology, alcoholism, and concomitant use with other drugs that lower the seizure threshold.

Rare reports of fatalities in association with seizures have been reported by foreign post-marketing surveillance, but not in U.S. clinical trials. In some of these cases, Anafranil had been administered with other epileptogenic agents; in others, the patients involved had possibly predisposing medical conditions. Thus a causal association between Anafranil treatment and these fatalities has not been established.

Physicians should discuss with patients the risk of taking Anafranil while engaging in activities in which sudden loss of consciousness could result in serious injury to the patient or others, e.g., the operation of complex machinery, driving, swimming, climbing.

PRECAUTIONS

General

Suicide: Since depression is a commonly associated feature of OCD, the risk of suicide must be considered. Prescriptions for Anafranil should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.

Cardiovascular Effects: Modest orthostatic decreases in blood pressure and modest tachycardia were each seen in approximately 20% of patients taking Anafranil in clinical trials; but patients were frequently asymptomatic. Among approximately 1400 patients treated with CMI in the premarketing experience who had ECGs, 1.5% developed abnormalities during treatment, compared with 3.1% of patients receiving active control drugs and 0.7% of patients receiving placebo. The most common ECG changes were PVCs, ST-T wave changes, and intraventricular conduction abnormalities. These changes were rarely associated with significant clinical symptoms. Nevertheless, caution is necessary in treating patients with known cardiovascular disease, and gradual dose titration is recommended.

Psychosis, Confusion, and Other Neuropsychiatric Phenomena: Patients treated with Anafranil have been reported to show a variety of neuropsychiatric signs and symptoms including delusions, hallucinations, psychotic episodes, confusion, and paranoia. Because of the uncontrolled nature of many of the studies, it is impossible to provide a precise estimate of the extent of risk imposed by treatment with Anafranil. As with tricyclic antidepressants to which it is closely related, Anafranil may precipitate an acute psychotic episode in patients with unrecognized schizophrenia.

Mania/Hypomania: During premarketing testing of Anafranil in patients with affective disorder, hypomania or mania was precipitated in several patients. Activation of mania or hypomania has also been reported in a small proportion of patients with affective disorder treated with marketed tricyclic antidepressants, which are closely related to Anafranil.

Hepatic Changes: During premarketing testing, Anafranil was occasionally associated with

elevations in SGOT and SGPT (pooled incidence of approximately 1% and 3%, respectively) of potential clinical importance (i.e., values greater than 3 times the upper limit of normal). In the vast majority of instances, these enzyme increases were not associated with other clinical findings suggestive of hepatic injury; moreover, none were jaundiced. Rare reports of more severe liver injury, some fatal, have been recorded in foreign postmarketing experience. Caution is indicated in treating patients with known liver disease, and periodic monitoring of hepatic enzyme levels is recommended in such patients.

Hematologic Changes: Although no instances of severe hematologic toxicity were seen in the premarketing experience with Anafanil, there have been postmarketing reports of leukopenia, agranulocytosis, thrombocytopenia, anemia, and pancytopenia in association with Anafanil use. As is the case with tricyclic antidepressants to which Anafanil is closely related, leukocyte and differential blood counts should be obtained in patients who develop fever and sore throat during treatment with Anafanil.

Central Nervous System: More than 30 cases of hyperthermia have been recorded by nondomestic postmarketing surveillance systems. Most cases occurred when Anafanil was used in combination with other drugs. When Anafanil and a neuroleptic were used concomitantly, the cases were sometimes considered to be examples of a neuroleptic malignant syndrome.

Sexual Dysfunction: The rate of sexual dysfunction in male patients with OCD who were treated with Anafanil in the premarketing experience was markedly increased compared with placebo controls (i.e., 42% experienced ejaculatory failure and 20% experienced impotence, compared with 2.0% and 2.6%, respectively, in the placebo group). Approximately 85% of males with sexual dysfunction chose to continue treatment.

Weight Changes: In controlled studies of OCD, weight gain was reported in 18% of patients receiving Anafanil, compared with 1% of patients receiving placebo. In these studies, 28% of patients receiving Anafanil had a weight gain of at least 7% of their initial body weight, compared with 4% of patients receiving placebo. Several patients had weight gains in excess of 25% of their initial body weight. Conversely, 5% of patients receiving Anafanil and 1% receiving placebo had weight losses of at least 7% of their initial body weight.

Electroconvulsive Therapy: As with closely related tricyclic antidepressants, concurrent administration of Anafanil with electroconvulsive therapy may increase the risks; such treatment should be limited to those patients for whom it is essential, since there is limited clinical experience.

Surgery: Prior to elective surgery with general anesthetics, therapy with Anafanil should be discontinued for as long as is clinically feasible, and the anesthesiologist should be advised.

Use in Concomitant Illness: As with closely related tricyclic antidepressants, Anafanil should be used with caution in the following:

- (1) Hyperthyroid patients or patients receiving thyroid medication, because of the possibility of cardiac toxicity;
- (2) Patients with increased intraocular pressure, a history of narrow-angle glaucoma, or urinary retention, because of the anticholinergic properties of the drug;
- (3) Patients with tumors of the adrenal medulla (e.g., pheochromocytoma, neuroblastoma) in whom the drug may provoke hypertensive crises;
- (4) Patients with significantly impaired renal function.

Withdrawal Symptoms: A variety of withdrawal symptoms have been reported in association with abrupt discontinuation of Anafanil, including dizziness, nausea, vomiting, headache, malaise, sleep disturbance, hyperthermia, and irritability. In addition, such patients may experience a worsening of psychiatric status. While the withdrawal effects of Anafanil have not been systematically evaluated in controlled trials, they are well known with closely related tricyclic antidepressants, and it is recommended that the dosage be tapered gradually and the patient monitored carefully during discontinuation (see DRUG ABUSE AND DEPENDENCE).

Information for Patients

Physicians are advised to discuss the following issues with patients for whom they prescribe Anafanil:

- (1) The risk of seizure (see WARNINGS);
- (2) The relatively high incidence of sexual dysfunction among males (see Sexual Dysfunction);
- (3) Since Anafanil may impair the mental and/or physical abilities required for the performance of complex tasks, and since Anafanil is associated with a risk of seizures, patients should be cautioned about the performance of complex and hazardous tasks (see WARNINGS);
- (4) Patients should be cautioned about using alcohol, barbiturates, or other CNS depressants concurrently, since Anafanil may exaggerate their response to these drugs;
- (5) Patients should notify their physician if they become pregnant or intend to become pregnant during therapy;
- (6) Patients should notify their physician if they are breast-feeding.

Drug Interactions

The risks of using Anafanil in combination with other drugs have not been systematically evaluated. Given the primary CNS effects of Anafanil, caution is advised in using it concomitantly with other CNS-active drugs (see Information for Patients). Anafanil should not be used with MAO inhibitors (see CONTRAINDICATIONS).

Close supervision and careful adjustment of dosage are required when Anafanil is administered with anticholinergic or sympathomimetic drugs.

Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.

The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methyphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).

Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7%-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.

Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition. Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCA metabolism. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary). Concomitant use of agents in the tricyclic antidepressant class (which includes Anafanil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug. Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required. It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic antidepressant class including Anafanil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).

Because Anafanil is highly bound to serum protein, the administration of Anafanil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects. Conversely, adverse effects may result from displacement of protein-bound Anafanil by other highly bound drugs (see CLINICAL PHARMACOLOGY, Distribution).

Carcinogenesis, Mutagenesis, Impairment of Fertility

No evidence of carcinogenicity was found in two 2-year bioassays in rats at doses up to 100 mg/kg, which is 24 and 4 times the maximum recommended human daily dose (MRHD) on a mg/kg and mg/m² basis, respectively, or in a 2-year bioassay in mice at doses up to 80 mg/kg, which is 20 and 1.5 times the MRHD on a mg/kg and mg/m² basis, respectively.

In reproduction studies, no effects on fertility were found in rats given up to 24 mg/kg, which is 6 times, and approximately equal to, the MRHD on a mg/kg and mg/m² basis, respectively.

Pregnancy Category C

No teratogenic effects were observed in studies performed in rats and mice at doses up to 100 mg/kg, which is 24 times the maximum recommended human daily dose (MRHD) on a mg/kg basis and 4 times (rats) and 2 times (mice) the MRHD on a mg/m² basis. Slight non-specific embryo/fetotoxic effects were seen in the offspring of treated rats given 50 and 100 mg/kg and of treated mice given 100 mg/kg.

There are no adequate or well-controlled studies in pregnant women. Withdrawal symptoms, including jitteriness, tremor, and seizures, have been reported in neonates whose mothers had taken Anafanil until delivery. Anafanil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Anafanil has been found in human milk. Because of the potential for adverse reactions, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

In a controlled clinical trial in children and adolescents (10-17 years of age), 46 outpatients received Anafanil for up to 8 weeks. In addition, 150 adolescent patients have received Anafanil in open-label protocols for periods of several months to several years. Of the 196 adolescents studied, 50 were 13 years of age or less and 146 were 14-17 years of age. The adverse reaction profile in this age group (see ADVERSE REACTIONS) is similar to that observed in adults.

The risks, if any, that may be associated with Anafanil's extended use in children and adolescents with OCD have not been systematically assessed. The evidence supporting the conclusion that Anafanil is safe for use in children and adolescents is derived from relatively short term clinical studies and from extrapolation of experience gained with adult patients. In particular, there are no studies that directly evaluate the effects of long term Anafanil use on the growth, development, and maturation of children and adolescents. Although there is no evidence to suggest that Anafanil adversely affects growth, development or maturation, the absence of such findings is not adequate to rule out a potential for such effects in chronic use.

The safety and effectiveness in pediatric patients below the age of 10 have not been established. Therefore, specific recommendations cannot be made for the use of Anafanil in pediatric patients under the age of 10.

Use in Elderly

Anafanil has not been systematically studied in older patients; but 152 patients at least 60 years of age participating in U.S. clinical trials received Anafanil for periods of several months to several years. No unusual age-related adverse events have been identified in this elderly population, but these data are insufficient to rule out possible age-related differences, particularly in elderly patients who have concomitant systemic illnesses or who are receiving other drugs concomitantly.

ADVERSE REACTIONS

Commonly Observed

The most commonly observed adverse events associated with the use of Anafanil and not seen at an equivalent incidence among placebo-treated patients were gastrointestinal complaints, including dry mouth, constipation, nausea, dyspepsia, and anorexia; nervous system complaints, including somnolence, tremor, dizziness, nervousness, and myoclonus; genitourinary complaints, including changed libido, ejaculatory failure, impotence, and micturition disorder; and other miscellaneous complaints, including fatigue, sweating, increased appetite, weight gain, and visual changes.

Leading to Discontinuation of Treatment

Approximately 20% of 3616 patients who received Anafanil in U.S. premarketing clinical trials discontinued treatment because of an adverse event. Approximately one-half of the patients who discontinued (9% of the total) had multiple complaints, none of which could be

Anafranil®
clomipramine hydrochloride

classified as primary. Where a primary reason for discontinuation could be identified, most patients discontinued because of nervous system complaints (5.4%), primarily somnolence. The second-most-frequent reason for discontinuation was digestive system complaints (1.3%), primarily vomiting and nausea.

Incidence in Controlled Clinical Trials

The following table enumerates adverse events that occurred at an incidence of 1% or greater among patients with OCD who received Anafranil in adult or pediatric placebo-controlled clinical trials. The frequencies were obtained from pooled data of clinical trials involving either adults receiving Anafranil (N=322) or placebo (N=319) or children treated with Anafranil (N=46) or placebo (N=44). The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the populations studied.

**Incidence of Treatment-Emergent Adverse Experience
 in Placebo-Controlled Clinical Trials
 (Percentage of Patients Reporting Event)**

Body System/ Adverse Event*	Adults		Children and Adolescents	
	Anafranil (N=322)	Placebo (N=319)	Anafranil (N=46)	Placebo (N=44)
Nervous System				
Somnolence	54	16	46	11
Tremor	54	2	33	2
Dizziness	54	14	41	14
Headache	52	41	28	34
Insomnia	25	15	11	7
Libido change	21	3	-	-
Nervousness	18	2	4	2
Myoclonus	13	-	2	-
Increased appetite	11	2	-	-
Paresthesia	9	3	2	2
Memory impairment	9	1	7	2
Anxiety	9	4	2	-
Twitching	7	1	4	5
Impaired concentration	5	2	-	-
Depression	5	1	-	-
Hypertonia	4	1	2	-
Sleep disorder	4	-	9	5
Psychosomatic disorder	3	-	-	-
Yawning	3	-	-	-
Confusion	3	-	2	-
Speech disorder	3	-	-	-
Abnormal dreaming	3	-	-	2
Agitation	3	-	-	-
Migraine	3	-	-	-
Depersonalization	2	-	2	-
Irritability	2	2	2	-
Emotional lability	2	-	-	2
Panic reaction	1	-	2	-
Aggressive reaction	-	-	2	-
Paresis	-	-	2	-
Skin and Appendages				
Increased sweating	29	3	9	-
Rash	8	1	4	2
Pruritus	6	-	2	2
Dermatitis	2	-	-	2
Acne	2	2	-	5
Dry skin	2	-	-	5
Urticaria	1	-	-	-
Abnormal skin odor	-	-	2	-
Digestive System				
Dry mouth	84	17	63	16
Constipation	47	11	22	9
Nausea	33	14	9	11
Dyspepsia	22	10	13	2
Diarrhea	13	9	7	5
Anorexia	12	-	22	2
Abdominal pain	11	9	13	18
Vomiting	7	2	7	-
Flatulence	6	3	-	2
Tooth disorder	5	-	-	-
Gastrointestinal disorder	2	-	-	2
Dysphagia	2	-	-	-
Esophagitis	1	-	-	-
Eructation	-	-	2	2
Ulcerative stomatitis	-	-	2	-
Body as a Whole				
Fatigue	39	18	35	9
Weight increase	18	1	2	-
Flushing	8	-	7	-
Hot flushes	5	-	2	-

Chest pain	4	4	7	-
Fever	4	-	2	7
Allergy	3	3	7	5
Pain	3	2	4	2
Local edema	2	4	-	-
Chills	2	1	-	-
Weight decrease	-	-	7	-
Otitis media	-	-	4	5
Asthenia	-	-	2	-
Halitosis	-	-	2	-
Cardiovascular System				
Postural hypotension	6	-	4	-
Palpitation	4	2	4	-
Tachycardia	4	-	2	-
Syncope	-	-	2	-
Respiratory System				
Pharyngitis	14	9	-	5
Rhinitis	12	10	7	9
Sinusitis	6	4	2	5
Coughing	6	6	4	5
Bronchospasm	2	-	7	2
Epistaxis	2	-	-	2
Dyspnea	-	-	2	-
Laryngitis	-	1	2	-
Urogenital System				
<i>Male and Female Patients Combined</i>				
Micturition disorder	14	2	4	2
Urinary tract infection	6	1	-	-
Micturition frequency	5	3	-	-
Urinary retention	2	-	7	-
Dysuria	2	2	-	-
Cystitis	2	-	-	-
<i>Female Patients Only (N=182) (N=167) (N=10) (N=21)</i>				
Dysmenorrhea	12	14	10	10
Lactation (nonpuerperal)	4	-	-	-
Menstrual disorder	4	2	-	-
Vaginitis	2	-	-	-
Leukorrhea	2	-	-	-
Breast enlargement	2	-	-	-
Breast pain	1	-	-	-
Menorrhagia	1	-	-	-
<i>Male Patients Only (N=140) (N=152) (N=36) (N=23)</i>				
Ejaculation failure	42	2	6	-
Impotence	20	3	-	-
Special Senses				
Abnormal vision	18	4	7	2
Taste perversion	8	-	4	-
Tinnitus	6	-	4	-
Abnormal lacrimation	3	2	-	-
Mydriasis	2	-	-	-
Conjunctivitis	1	-	-	-
Anisocoria	-	-	2	-
Blepharospasm	-	-	2	-
Ocular allergy	-	-	2	-
Vestibular disorder	-	-	2	2
Musculoskeletal				
Myalgia	13	9	-	-
Back pain	6	6	-	-
Arthralgia	3	5	-	-
Muscle weakness	1	-	2	-
Hemic and Lymphatic				
Purpura	3	-	-	-
Anemia	-	-	2	2
Metabolic and Nutritional				
Thirst	2	2	-	2

* Events reported by at least 1% of Anafranil patients are included.

Other Events Observed During the Premarketing Evaluation of Anafranil
 During clinical testing in the U.S., multiple doses of Anafranil were administered to approximately 3600 subjects. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.

In the tabulations that follow, a modified World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the 3525 individuals exposed to Anafranil who experienced an event of the type cited on at least one occasion while receiving Anafranil. All events are included except those already listed in the previous table, those reported in terms so general as to be uninformative, and those in which an association with the drug was remote. It is important to emphasize that although the events reported occurred during treatment with Anafranil, they were not necessarily caused by it.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in less than 1/1000 patients. **Body as a Whole:** Infrequent - general edema, increased susceptibility to infection, malaise. Rare - dependent edema, withdrawal syndrome.

DESC
Anafr
(dibe
avail
Cl
diben

C
water
mole
h
Blue
para
diox
CLM
Pha
Cior
its e
unk
imp
Ph
Abs
sol

trat
maj
the
Cst
tor
terr
the
rec
PR

ho
ple
fro
(m
fro
D
D
C
Th
at
M
cu
ur
Al
ck
st
ck
at
E
al
ci
n
1
e
n
c
a
n
r
t
c
/
/
/
/



89000602



89000602

Continuation could be identified, most
patients (5.4%), primarily somnolence.
Other digestive system complaints

Observed at an incidence of 1% or
greater in adult or pediatric placebo-con-
trolled pooled data of clinical trials involv-
ing 319 patients or children treated with
Anafanil. It should be aware that these figures can-
not be taken as a guide to the expected course of
usual medical practice, in those that prevailed in
the clinical studies. The cited figures are
based on figures obtained from other studies
and investigators. The cited figures are
estimates of the relative contribution of
each event to the total number of events in
the populations studied.

**Adverse Experience
(Estimated Frequency of
Occurring Event)**

Children and Adolescents

Event	Anafanil (N=46)	Placebo (N=44)
Chest pain	4	11
Fever	4	2
Allergy	3	4
Pain	3	2
Local edema	2	4
Chills	2	1
Weight decrease	-	-
Otitis media	-	-
Asthenia	-	-
Halitosis	-	-
Cardiovascular System		
Postural hypotension	6	-
Palpitation	4	2
Tachycardia	4	-
Syncope	-	-
Respiratory System		
Pharyngitis	14	9
Rhinitis	12	10
Sinusitis	6	4
Coughing	6	6
Bronchospasm	2	-
Epistaxis	2	-
Dyspnea	-	-
Laryngitis	-	1
Urogenital System		
Male and Female Patients Combined		
Micturition disorder	14	2
Urinary tract infection	6	1
Micturition frequency	5	3
Urinary retention	2	-
Dysuria	2	2
Cystitis	2	-
Female Patients Only (N=182)		(N=167)
Dysmenorrhea	12	14
Lactation (nonpuerperal)	4	-
Menstrual disorder	4	2
Vaginitis	2	-
Leukorrhea	2	-
Breast enlargement	2	-
Breast pain	1	-
Amenorrhea	1	-
Male Patients Only (N=140)		(N=152)
Ejaculation failure	42	2
Impotence	20	3
Special Senses		
Abnormal vision	18	4
Taste perversion	8	-
Tinnitus	6	-
Abnormal lacrimation	3	2
Mydriasis	2	-
Conjunctivitis	1	-
Anisocoria	-	-
Blepharospasm	-	-
Ocular allergy	-	-
Vestibular disorder	-	-
Musculoskeletal		
Myalgia	13	9
Back pain	6	6
Arthralgia	3	5
Muscle weakness	1	-
Hemic and Lymphatic		
Purpura	3	-
Anemia	-	-
Metabolic and Nutritional		
Thirst	2	2
Other Events		
Headache	63	16
Constipation	22	9
Drowsiness	9	11
Nausea	13	2
Abnormal electrocardiogram	7	5
Abnormal blood chemistry	22	2
Abnormal urinalysis	13	16
Abnormal chest x-ray	7	-
Abnormal pulmonary function tests	-	2
Abnormal skin tests	-	-
Abnormal histamine sensitivity	-	2
Abnormal ocular examination	2	2
Abnormal ear, nose and throat examination	2	-
Abnormal dental examination	35	9
Abnormal hearing	2	-
Abnormal vision	7	-
Abnormal taste	2	-

Chest pain	4	4	7	-
Fever	4	-	2	7
Allergy	3	3	7	5
Pain	3	2	4	2
Local edema	2	4	-	-
Chills	2	1	-	-
Weight decrease	-	-	7	-
Otitis media	-	-	4	5
Asthenia	-	-	2	-
Halitosis	-	-	2	-
Cardiovascular System				
Postural hypotension	6	-	4	-
Palpitation	4	2	4	-
Tachycardia	4	-	2	-
Syncope	-	-	2	-
Respiratory System				
Pharyngitis	14	9	-	5
Rhinitis	12	10	7	9
Sinusitis	6	4	2	5
Coughing	6	6	4	5
Bronchospasm	2	-	7	2
Epistaxis	2	-	-	2
Dyspnea	-	-	2	-
Laryngitis	-	1	2	-
Urogenital System				
Male and Female Patients Combined				
Micturition disorder	14	2	4	2
Urinary tract infection	6	1	-	-
Micturition frequency	5	3	-	-
Urinary retention	2	-	7	-
Dysuria	2	2	-	-
Cystitis	2	-	-	-
Female Patients Only (N=182)		(N=167)	(N=10)	(N=21)
Dysmenorrhea	12	14	10	10
Lactation (nonpuerperal)	4	-	-	-
Menstrual disorder	4	2	-	-
Vaginitis	2	-	-	-
Leukorrhea	2	-	-	-
Breast enlargement	2	-	-	-
Breast pain	1	-	-	-
Amenorrhea	1	-	-	-
Male Patients Only (N=140)		(N=152)	(N=36)	(N=23)
Ejaculation failure	42	2	6	-
Impotence	20	3	-	-
Special Senses				
Abnormal vision	18	4	7	2
Taste perversion	8	-	4	-
Tinnitus	6	-	4	-
Abnormal lacrimation	3	2	-	-
Mydriasis	2	-	-	-
Conjunctivitis	1	-	-	-
Anisocoria	-	-	2	-
Blepharospasm	-	-	2	-
Ocular allergy	-	-	2	-
Vestibular disorder	-	-	2	2
Musculoskeletal				
Myalgia	13	9	-	-
Back pain	6	6	-	-
Arthralgia	3	5	-	-
Muscle weakness	1	-	2	-
Hemic and Lymphatic				
Purpura	3	-	-	-
Anemia	-	-	2	2
Metabolic and Nutritional				
Thirst	2	2	-	2

*Events reported by at least 1% of Anafanil patients are included.

Other Events Observed During the Premarketing Evaluation of Anafanil
During clinical testing in the U.S., multiple doses of Anafanil were administered to approximately 3600 subjects. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.

In the tabulations that follow, a modified World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the 3525 individuals exposed to Anafanil who experienced an event of the type cited on at least one occasion while receiving Anafanil. All events are included except those already listed in the previous table, those reported in terms so general as to be uninformative, and those in which an association with the drug was remote. It is important to emphasize that although the events reported occurred during treatment with Anafanil, they were not necessarily caused by it.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in less than 1/1000 patients.
Body as a Whole: Infrequent - general edema, increased susceptibility to infection, malaise. Rare - dependent edema, withdrawal syndrome.